Independent report · Healthcare

Creador and Leeford Healthcare: Reported talks: about ₹800 Cr for about

· By Abhinav

Leeford Healthcare management at a product launch · Image: Indian Pharma Post

Leeford Healthcare management at a product launch · Image: Indian Pharma Post

Independent report content

STATUSTALKS ONLY. All coverage is from the Economic Times via Venture Intelligence (4 Aug), Digital Health News and Medical Dialogues (8 Aug). No signing, closing or company confirmation was found
TARGETLeeford Healthcare Ltd, Ludhiana, unlisted branded-generics and pharma company founded 2006 · founder Jiwan Lal Gupta, reportedly with nearly 88% held by the family
INVESTORCreador, Kuala Lumpur-based private equity firm founded 2011 · Creador VI closed at US$930m (Jan 2025) against a US$750m target
REPORTED TERMSAbout ₹800 Cr for about 10% · valuation ₹8,000–8,500 Cr · primary versus secondary split and use of money not reported
FINANCIALS (FY25)Operating income about ₹1,718 Cr · PAT about ₹240 Cr (Venture Intelligence, citing ET) · other sources give ₹1,500–1,750 Cr or ₹2,000 Cr turnover
OPERATIONS1,950+ products in 75+ therapeutic categories, 7+ plants, 12 lakh+ pharmacies, 5,000+ staff, exports to about 10–11 countries (2025 promotional figures)
COMPARABLECreador bought about 7% of La Renon Healthcare in Dec 2025 at an implied ₹11,000 Cr
CONFLICTMedical Dialogues calls this Leeford's first outside equity; Venture Intelligence reports about US$88m from TA Associates in 2019
THE ACCESS POINT Leeford is unlisted and no deal has been confirmed. There is no way for outside investors to buy into it directly.

Executive decision summary

THE BOTTOM LINECreador, a Malaysia-based private equity firm, is reported to be in talks to invest about ₹800 crore for about 10% of Leeford Healthcare, a Ludhiana drug maker, at a valuation of ₹8,000 to ₹8,500 crore. The reports come from the Economic Times through Venture Intelligence on 4 August 2026 and from Medical Dialogues and Digital Health News in the following days. Neither company has confirmed, no filing exists and the reports do not say whether the money is new capital or a sale by the founder family. Leeford had operating income of about ₹1,718 crore and a profit of about ₹240 crore in FY25, according to the ET figures, which puts the price at about 33 to 35 times profit. Sources also disagree on whether this would be Leeford's first outside investor. This note is therefore about reported talks and what the numbers imply, not a completed deal.
WHICH INVESTORLeeford fits a watch-list IF you track mid-cap pharma private equity and want to see whether the talks become a signed deal. Wait IF you need a confirmed investment, a split between new and existing shares or an EBITDA figure: none was found.
COMFORT FITBranded generics = off-patent medicines sold under the company's own brand name and promoted to doctors. Valuation = the total value put on the company. ₹800 Cr for 10% implies ₹8,000 Cr. Primary versus secondary = new money into the company versus a sale by existing holders. In talks = discussions are reported but nothing has been agreed or announced by the parties.
THE RUPEIA NUMBER33x to 35x. The reported valuation of ₹8,000–8,500 Cr divided by FY25 profit of about ₹240 Cr, if the ET profit figure is right.

1 CLAIM REGISTER: EVIDENCE GRADING

ClaimSourceGradeRupeia assessment
Creador in talks to invest about ₹800 Cr for about 10%Venture Intelligence (4 Aug, citing ET); Medical Dialogues (8 Aug); Digital Health NewsCReported talks, unconfirmed
Valuation ₹8,000–8,500 CrMedical Dialogues; DHNCBody gives a range; Venture Intelligence states none
FY25 operating income about ₹1,718 Cr, PAT about ₹240 CrVenture Intelligence citing ETDSingle source
First external equity since 2006Medical Dialogues; DHNDConflicts with a TA Associates report
US$88m from TA Associates in Oct 2019Venture IntelligenceDSingle source; two searches found no other
Promoter holding about 88%Medical Dialogues; DHNDNot checked against a shareholding filing

2 THE REPORTED TERMS AND WHAT THEY IMPLY

Leeford Healthcare's office · Image: Digital Health News
Leeford Healthcare's office · Image: Digital Health News
ItemDetail
Amount and stakeAbout ₹800 Cr for about 10%
Valuation₹8,000–8,500 Cr (headline ₹8,500 Cr)
Seller or new moneyNot reported
ReportsVenture Intelligence 4 Aug 2026; Digital Health News (updated 4 Aug); Medical Dialogues 8 Aug
Use of moneyNot reported
Calculation (Rupeia)Result
Implied valuation at ₹800 Cr for 10%₹800 Cr ÷ 10% = ₹8,000 Cr
Stake at the ₹8,500 Cr valuation₹800 Cr ÷ ₹8,500 Cr = 9.4%
Price to earnings (FY25 PAT ₹240 Cr)₹8,000 Cr = 33.3x; ₹8,500 Cr = 35.4x
Price to operating income (₹1,718 Cr)4.7x to 4.9x
PAT margin on operating income₹240 Cr ÷ ₹1,718 Cr = 14.0%
Promoter stake after a 10% sale, if about 88% now88% − 10% = 78% if all secondary; 88% × 0.9 = 79.2% if all primary
RUPEIA READ The deal size is modest for the target: 10% of a company worth about ₹8,000 crore. A minority stake at 33 to 35 times profit says the investor is paying for growth and a clean balance sheet, not for control. The reported figures cannot show whether the price is high or low, because no EBITDA, debt or FY26 number was found.

3 WHAT LEEFORD IS

ItemDetailSource quality
BusinessLudhiana company founded 2006 in branded and generic pharma; divisions include Cosmacia (personal care), Esencia and Medisciences (nephrology and urology)DHN; company site
Scale (promotional, May 2025)1,950+ products; 75+ therapeutic categories; 7+ manufacturing units; 12 lakh+ pharmacies and 5 lakh+ general stores; 5,000+ staff; exports to over 11 countriesMumbai Messenger; the corporate site says 10 overseas destinations
Revenue figures₹1,718 Cr operating income (ET); ₹1,500–1,750 Cr (Tofler); ₹2,000 Cr turnover (undated promotional claim)Conflicting
Investment plan₹200 Cr over three years for an orthopaedic and mobility aids division, announced 9 Jan 2026Indian Pharma Post
ManagementFounder Jiwan Lal Gupta; directors include Neha Gupta, Sidhant Gupta, Sukhdeep Singh and Amit Kumar (MD)Tofler
Not foundBrand list, field-force count, export country list, plant list, EBITDA, FY26 results
Calculation (Rupeia)Result
Range of FY25 revenue claims₹1,500 Cr to ₹2,000 Cr is a spread of about 33%
Orthopaedic investment against FY25 income₹200 Cr over three years ≈ ₹67 Cr a year, about 4% of operating income
Staff productivity₹1,718 Cr ÷ 5,000 staff ≈ ₹34 lakh of income per person (promotional headcount)
RUPEIA READ Leeford's public profile is promotional, and the financial figures differ by source. The most useful figure is the ET one, but it is a single source and a filing has not been seen. Promoter holding near 88% means the founder family still controls the company, which is typical for a family-owned manufacturer at this stage.

4 THE INVESTOR: CREADOR'S RECORD AND POWDER

ItemDetailSource
Creador VIClosed at US$930m against a US$750m target, reported as hard-capped; investors include ADB, IFC and FinDev CanadaDakota, 22 Jan 2025
Earlier fundsFund IV about US$565m (above a US$550m hard cap); Fund V US$700m per PitchBook; over US$3.1bn across six funds per one profileDakota; PitchBook
Exits40 per PitchBook against 7 per CB Insights; counts conflictPaid data not accessed
La Renon HealthcareAbout 7% bought from the promoter and Peak XV, announced 8 Dec 2025; reported about ₹770 Cr; WhiteOak and Siguler Guff about 3% for about ₹330 Cr; implied value about ₹11,000 Cr; earlier value about ₹8,000 Cr (Feb 2025)DealStreetAsia; The Star; ET-based summaries
Other healthcareParas Healthcare secondary (Apr 2025); a minority stake in an Indian hospital chainPitchBook; AVCJ
Calculation (Rupeia)Result
Creador VI against its target930 ÷ 750 − 1 = +24%
Fund VI in rupees at ₹96.5 per US$About ₹8,975 Cr
Leeford cheque against Fund VI₹800 Cr ÷ ₹8,975 Cr = 8.9%
La Renon cheque against Fund VI₹770 Cr ÷ ₹8,975 Cr = 8.6%; both together 17.5%
La Renon implied value₹770 Cr ÷ 7% = ₹11,000 Cr; ₹330 Cr ÷ 3% = ₹11,000 Cr
La Renon value step-up₹11,000 Cr ÷ ₹8,000 Cr − 1 = 37.5% in about ten months
RUPEIA READ If both deals close, Creador would put about 17% of its sixth fund into two Indian pharma companies in eight months, each at a roughly similar ticket. That is a concentrated sector bet for a fund described as focused on South and Southeast Asia more broadly, and it fits the wider 2026 pattern of private equity buying minority stakes in profitable mid-cap pharma.

5 THE 2026 PHARMA DEAL CONTEXT

DealDetailSource quality
ChrysCapital and Novartis India70.68% for about ₹1,446 Cr; agreed Feb 2026 (Report 56)Press
Warburg Pincus and IntegraceAbout ₹1,200 Cr; one report says acquired in July 2026, another pendingConflicting
Warburg Pincus and Maneesh PharmaFormulations business, ₹1,600–1,800 Cr; advanced discussions in March 2026; no close foundPress
Quadria-led consortium and Samarth Lifesciences80–85% at about ₹4,500 Cr valuation; under consideration in April 2026Medical Dialogues
RMB Capitalworks and Biodeal Pharma₹385 Cr raise, Aug 2026; stake undisclosedPress
Anupam Rasayan and Bliss GVSControl for about ₹1,750 Cr (Report 57)Press
RUPEIA READ A mid-cap pharma investor in 2026 has many deals to compare. The Leeford price of 33 to 35 times profit is not obviously out of line with the sector, but without EBITDA or growth figures, the comparison to peers on a multiple of operating profit cannot be made.

6 RISKS, SCENARIOS AND CHECKLIST

RiskEvidenceSeverityKill condition
Deal may not happenTalks only; no confirmation or filingHIGHTalks lapse
Single-source financialsFY25 income and profit from one reportHIGHFilings show lower figures
Family-business governancePromoter holding about 88%; family directorsMEDIUMRelated-party issues
Valuation33–35x profit with no EBITDA dataMEDIUMGrowth below expectation
Conflicting historyFirst-investor claim vs TA Associates 2019 reportLOWEarlier investor terms limit rights
Promotional dataReach and product figures from marketing materialMEDIUMOperating data differs
ScenarioWhat happensOutcome
BullDeal signs at about ₹8,000–8,500 Cr; capital funds new divisionsGrowth phase
BaseDeal signs later at a lower price or smaller stakeModest minority stake
BearTalks failLeeford continues as a family-owned company
Investor classFitWhy
Pharma private-equity watcherFITFits a clear 2026 pattern of minority stakes
Listed-market investorINFORMATIONALValuation reference for listed mid-cap pharma
Retail investorNOT AVAILABLECompany is unlisted and no deal is confirmed

Rupeia does not recommend buying or selling any security and is not a SEBI-registered investment adviser or research analyst. This note describes reported talks. Open items are confirmation, the primary-secondary split and Leeford's EBITDA.

7 KEY TERMS USED IN THIS REPORT

The terms below are used in this report. Each is explained in plain words.

TermMeaning
Branded genericsOff-patent medicines sold under a company's own brand name.
Minority stakeA holding below 50% that does not give control.
ValuationThe total value placed on a company; implied by price paid for a share of it.
Primary and secondaryNew money for the company versus sale by existing holders.
Hard capA ceiling a fund sets on its total size.
Implied valueThe value of 100% of a company calculated from a price paid for a part.

Frequently asked questions

Has Creador invested in Leeford Healthcare?

Not on the sources read. Reports from 4 to 8 August 2026 say Creador is in talks; no signing or closing has been reported and neither company has confirmed.

What are the reported terms?

About ₹800 crore for about 10% of Leeford at a valuation of ₹8,000 to ₹8,500 crore.

What does Leeford earn?

FY25 operating income of about ₹1,718 crore and profit of about ₹240 crore according to the Economic Times via Venture Intelligence. Other sources give different revenue figures.

Who owns Leeford?

Founder Jiwan Lal Gupta and family, reportedly holding nearly 88%, according to Medical Dialogues and Digital Health News.

What did Creador do in La Renon Healthcare?

It bought about 7% from the promoter and Peak XV, announced on 8 December 2025, at an implied company value of about ₹11,000 crore.

Is this Leeford's first outside investment?

Two outlets say so, but Venture Intelligence reports about US$88 million from TA Associates in October 2019. The sources conflict.

Source log

Medical Dialogues: Creador in talks to invest ₹800 crore in Leeford Healthcare for 10% stake at ₹8,500 crore valuation

Venture Intelligence: Creador in talks to invest ₹800 Cr in Leeford Healthcare

Digital Health News: Creador eyes ₹800 Cr bet on Leeford Health

Indian Pharma Post: Leeford Healthcare bets ₹200 crore on orthopedic and mobility aids

Tofler: Leeford Healthcare Ltd company page

DealStreetAsia: Creador acquires 7% stake in India's La Renon Healthcare from promoter, Peak XV

Dakota: Creador closes sixth flagship fund oversubscribed at US$930M

DISCLAIMER This document is published strictly for informational, educational and academic record-keeping purposes. The publisher is not a SEBI Registered Investment Adviser (RIA) or Research Analyst (RA). It does not constitute personal investment advice, a financial recommendation, or an offer or solicitation to buy, sell or subscribe to any securities. Investments in the securities market are subject to market risks. Read all related documents carefully before investing.